Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03035955 · ClinicalTrials.gov registry record · Phase 2

Azelaic Acid on Demodex Counts in Rosacea

A Phase 2 study, sponsored by Wake Forest University.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT03035955: Completed Phase 2 study, sponsored by Wake Forest University.

NCT03035955 is a Phase 2 study that has completed, run by Wake Forest University. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03035955, a Phase 2 study, has completed, sponsored by Wake Forest University.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to measure the effects of azelaic acid on Demodex folliculorum counts and disease condition via a split face design in approximately twenty patients with mild to moderate rosacea. The investigators hypothesize that treatment of rosacea with azelaic acid will lead to a decreased Demodex folliculorum count as well as an improvement in lesion count and redness.

Primary Outcome

number of demodex at Baseline and Week 4. Only Week 4 reported

Interventions

  • DRUG Azelaic acid

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2010-12
Est. Completion 2012-02-02
Phase Phase 2
Wake Forest University

100 total trials

What the finished NCT03035955 record still lists

NCT03035955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 1 intervention - of which Azelaic acid is the first listed.

NCT03035955 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03035955 about?

NCT03035955 is a clinical study titled "Azelaic Acid on Demodex Counts in Rosacea". The purpose of this study is to measure the effects of azelaic acid on Demodex folliculorum counts and disease condition via a split face design in approximately twenty patients with mild to moderate rosacea. The investigators hypothesize that treatment of rosacea with azelaic acid will lead to a de...

What is the current status of trial NCT03035955?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-12. Estimated completion is 2012-02-02.

What interventions are being tested in trial NCT03035955?

The interventions under investigation include: Azelaic acid (DRUG).

Who is sponsoring clinical trial NCT03035955?

This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03035955's enrollment target sits among peer trials

20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03035955, the US trial registry maintained by the National Library of Medicine. NCT03035955 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.